Enovis Divests Dr. Comfort Shoe Business for Up to $60 Million to Streamline Operations and Focus on Medical Devices

Enovis (ENOV) is divesting its Dr. Comfort diabetic footwear segment for up to $60 million to focus on its core healthcare business. The company operates primarily in the medical devices and instruments industry and faces financial challenges, with negative profitability metrics and a distressed Altman Z-Score. Enovis generates maximum revenue from the Prevention & Recovery segment and has a market capitalization of $1.73 billion.

Enovis (NYSE: ENOV), a medical technology company, has announced the sale of its Dr. Comfort diabetic footwear business to Promus Equity Partners for up to $60 million in cash. The transaction, which includes an upfront payment of $45 million and up to $15 million in milestone payments, will help Enovis refocus on its core Prevention & Recovery franchise Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million^[1].

The sale is part of Enovis' strategy to enhance profitability, expand margins, and accelerate debt reduction. The company expects to provide additional strategic commentary on the transaction during its third quarter results call on November 6, 2025, at 8:30 am ET Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million^[1].

Promus Equity Partners, a multi-family asset management firm based in Chicago with approximately $2.7 billion under management, will acquire the Dr. Comfort business. The firm is known for investing in buyouts, real estate, venture capital, and other asset classes Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million^[1].

Enovis operates primarily in the medical devices and instruments industry, generating maximum revenue from its Prevention & Recovery segment. The company has faced financial challenges, with negative profitability metrics and a distressed Altman Z-Score . The sale of the Dr. Comfort business is expected to help Enovis improve its financial performance.

Enovis' shares of common stock are listed on the New York Stock Exchange under the symbol ENOV, with a market capitalization of $1.73 billion .